Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 5/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842306 | 0.92 | PDPK1 (0.49) | LMNAGLP1RADRA2BADRA2CADRA1A | |
| SCHEMBL6100530 | 0.81 | LMNA (0.51) | LMNAGLP1RHDAC6KCNN3ADRA2A | |
| SCHEMBL6100784 | 0.77 | MEN1 (0.48) | LMNAGLP1RHDAC6KCNN3ADRA2A | |
| SCHEMBL6101973 | 0.76 | GLP1R (0.50) | LMNAGLP1RPFKFB3CNR1 | |
| SCHEMBL1976205 | 0.74 | PFKFB3 (0.57) | LMNAHDAC6KCNN3ADRA2AADRA2B | |
| SCHEMBL6102962 | 0.74 | KMT2A (0.47) | LMNAGLP1RPFKFB3MEN1KMT2A | |
| SCHEMBL30267946 | 0.73 | PFKFB3 (0.58) | LMNAPFKFB3 | |
| SCHEMBL30268481 | 0.73 | PFKFB3 (0.58) | LMNAPFKFB3 | |
| SCHEMBL30267939 | 0.73 | PFKFB3 (0.58) | LMNAPFKFB3 | |
| SCHEMBL3842498 | 0.73 | AURKA (0.44) | CNR1CNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | LMNA 4726/4885GLP1R 736/4885HDAC6 522/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | LMNA 4726/4885GLP1R 736/4885HDAC6 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.